Last 306.35 INR
Change Today +3.65 / 1.21%
Volume 61.5K
As of 7:32 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

venus remedies ltd (VNR) Snapshot

Open
304.60
Previous Close
302.70
Day High
312.90
Day Low
303.30
52 Week High
05/15/13 - 358.45
52 Week Low
08/2/13 - 140.00
Market Cap
3.5B
Average Volume 10 Days
252.6K
EPS TTM
58.80
Shares Outstanding
11.4M
EX-Date
09/23/13
P/E TM
5.2x
Dividend
3.00
Dividend Yield
0.98%
Current Stock Chart for VENUS REMEDIES LTD (VNR)

Related News

No related news articles were found.

venus remedies ltd (VNR) Related Businessweek News

No Related Businessweek News Found

venus remedies ltd (VNR) Details

Venus Remedies Limited manufactures and trades medicines in India and internationally. It primarily offers fixed dosage injectable products. The company’s product portfolio includes approximately 75 products in various therapeutic segments comprising oncology, anti infective, neurology, cardiology, orthopedic, pediatrics, and surgery. It offers its products under the Mebatic, Calridol, Moximicin, Neurotol, Glutapep, Doxol, Paxol, Citabol, Epirol, Ronem, Immunox, Pimcef, Fejet IV, Parin-E, Vanconex, Elores, Supime, Tobracef, Vancoplus, Potentox, Pirotum, and other brand names. The company was incorporated in 1989 and is headquartered in Panchkula, India.

Founded in 1989

venus remedies ltd (VNR) Top Compensated Officers

Chairman, Joint Managing Director, Chief Exec...
Total Annual Compensation: 5.7M
Joint Managing Director, Head of Venus Medici...
Total Annual Compensation: 4.6M
Chief Operating Officer, Vice President, Exec...
Total Annual Compensation: 2.4M
Deputy Managing Director, Executive Director ...
Total Annual Compensation: 2.7M
Compensation as of Fiscal Year 2013.

venus remedies ltd (VNR) Key Developments

Venus Remedies Ltd. - Shareholder/Analyst Call

Venus Remedies Ltd. - Shareholder/Analyst Call

Venus Remedies Ltd. Bags Marketing Approval from Myanmar for its Product Elores

Venus Remedies Ltd. announced the Venus bags marketing approval from Myanmar for its product Elores. The company plans to launch the drug in Myanmar by April. Elores has a unique profile of action, which gives it an edge over all the existing therapies, including carbapenems, considered tast-resorl drugs. This novel antibiotic adjuvant entity (AAE) has recorded reduction in treatment time and cost by up to 30%. It prevents both development and spread of bacterial resistance from one species to another, which makes it one of the safe drugs available to cater to multidrug-resistant and carbapenem-resistant enterobacteriaceae (cREs).

Venus Remedies Ltd. Reports Unaudited Provisional Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013

Venus Remedies Ltd. reported unaudited provisional earnings results for the third quarter and nine months ended December 31, 2013. For the quarter, the company reported net sales/income from operations of INR 1,304.58 million compared to INR 1,119.09 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 260.88 million against INR 218.93 million a year ago. Profit from ordinary activities before tax was INR 178.16 million compared to INR 169.44 million a year ago. Net profit was INR 172.28 million or INR 15.06 per basic share not annualized compared to INR 160.55 million or INR 16.48 per basic share not annualized a year ago. For the nine months, the company reported net sales/income from operations of INR 3,820.33 million compared to INR 3,349.47 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 708.72 million against INR 646.56 million a year ago. Profit from ordinary activities before tax was INR 491.41 million compared to INR 471.15 million a year ago. Net profit was INR 488.41 million or INR 40.94 per basic share not annualized compared to INR 451.92 million or INR 46.39 per basic share not annualized a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNR:IN 306.35 INR 0.00

VNR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNR.
View Industry Companies
 

Industry Analysis

VNR

Industry Average

Valuation VNR Industry Range
Price/Earnings 3.7x
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 2.8x
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENUS REMEDIES LTD, please visit www.venusremedies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.